Is Edgewise Therapeutics, Inc. (EWTX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.2% / 30% | 15.8% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 0.2% / 33% | 15.8% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 1.0% / 33% | 96.6% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.2% / 33% | 15.8% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 1.0% / 33% | 96.6% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -34.2% | |
| Return on Assets (ROA) | -23.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$144M |
| Free Cash Flow | -$144M |
| Total Debt | $4M |
| Debt-to-Equity | 0.8 |
| Current Ratio | 19.9 |
| Total Assets | $553M |
Price & Trading
| Last Close | $31.65 |
| 50-Day MA | $29.50 |
| 200-Day MA | $20.38 |
| Avg Volume | 1.1M |
| Beta | 0.3 |
|
52-Week Range
$10.60
| |
About Edgewise Therapeutics, Inc. (EWTX)
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Edgewise Therapeutics, Inc. (EWTX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Edgewise Therapeutics, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Edgewise Therapeutics, Inc.'s debt ratio?
Edgewise Therapeutics, Inc.'s debt ratio is 0.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.0%.
What are Edgewise Therapeutics, Inc.'s key financial metrics?
Edgewise Therapeutics, Inc. has a market capitalization of $3.3B. Return on equity stands at -34.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.